Dimitrios Tsilingiris

TL;DR: Available evidence regarding available surgical modalities and the mechanisms that drive metabolic amelioration after bariatric surgery are reviewed and reports from observational and randomized studies with regard to T2DM remission are reviewed.

TL;DR: In this paper, the authors present evidence-based recommendations on diagnostic and therapeutic work-up of VITT and discuss new dilemmas and perspectives that emerged after the description of this entity.

TL;DR: It has been suggested recently that follistatin and its homologous protein, follistsatin‐like 3 (FSTL3), may be a therapeutic target in the treatment of type 2 diabetes because of their glucose‐regulatory effects in rodents.

TL;DR: Low TcPO2 in subjects with DPN may contribute to delay in healing of diabetic foot ulcers, irrespectively of PAD, and presence of DPN is independently associated with impaired cutaneous perfusion.

TL;DR: The accumulation of evidence from the effect of exogenous administration of native gut peptides alone or in combinations to humans as well as the development of mimetic agents exerting agonistic effects on combinations of gut hormone receptors pave the way for future integrated gut peptide-based treatments, which may mimic the effects of bariatric surgery.